PharmaEngineROCO:4162 +4.43%78 Gross Margin % is 94.38% as of Dec. 2025, which is 1% below its 10-year median of 94.98. GuruFocus rates ROCO:4162 with a GF Score™ of 78/100 and a GF Value™ of NT$115.15 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 732 Biotechnology companies, PharmaEngine ranks better than 91.94% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
PharmaEngine had a gross margin of 94.38% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
PharmaEngine Gross Margin % Related Terms
PharmaEngine Gross Margin % Historical Data
* Premium members only.
The historical data trend for PharmaEngine's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4162 vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, PharmaEngine's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PharmaEngine Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PharmaEngine's Gross Margin % distribution charts can be found below:
* The bar in red indicates where PharmaEngine's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
PharmaEngine (ROCO:4162) has a Gross Margin % of 94.38% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on PharmaEngine and its competitors. This is near median its historical median of 94.98. Over the past decade, PharmaEngine's Gross Margin % has ranged from 89.87 to 99.82. According to the industry distribution chart, PharmaEngine ranks #59 out of 732 companies in the Biotechnology industry, placing it in the top 8.1%.
Is PharmaEngine's Gross Margin % too high?
PharmaEngine's current Gross Margin % of 94.38% is near median its 10-year median of 94.98. Over the past 10 years, this metric has ranged from a low of 89.87 to a high of 99.82. The Biotechnology industry median Gross Margin % is 60.91. PharmaEngine's value of 94.38% is 54.9% above this industry median. Based on the distribution chart, PharmaEngine ranks #59 out of 732 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, PharmaEngine has a GF Score™ of 78/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PharmaEngine's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, PharmaEngine ranks #59 out of 732 companies for Gross Margin %. This places PharmaEngine in the top 8% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 60.91. PharmaEngine's value of 94.38% is 54.9% above this benchmark. Historically, PharmaEngine's own Gross Margin % has ranged from 89.87 to 99.82 over the past decade. While the company's 10-year median is 94.98 vs. the industry median of 60.91, PharmaEngine has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 732 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PharmaEngine's current Gross Margin % of 94.38% is 54.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on PharmaEngine and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PharmaEngine's current Gross Margin % is 94.38%, which is near median its own 10-year median of 94.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaEngine stock overvalued right now?
Based on GuruFocus' analysis, PharmaEngine (ROCO:4162) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$115.15, compared to a current price of NT$63.70 — trading 44.7% below its estimated fair value. The current Gross Margin % is 94.38%, which is near median its 10-year median of 94.98 and 54.9% above the Biotechnology industry median of 60.91. PharmaEngine's overall GF Score™ is 78/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For PharmaEngine (ROCO:4162), the current Gross Margin % is 94.38% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PharmaEngine (ROCO:4162) Overvalued in 2026?
Based on GuruFocus' analysis, PharmaEngine stock appears to be undervalued.
The current stock price of NT$63.70 is trading 44.7% below its estimated GF Value™ of NT$115.15.
GuruFocus considers PharmaEngine to be Significantly Undervalued.
Key valuation signals for ROCO:4162:
Gross Margin %: 94.38% (near median its 10-year median of 94.98)
GF Value™: NT$115.15 vs. price of NT$63.70 (44.7% below fair value)
Industry Position: 54.9% above the Biotechnology median (#59 of 732)
No single metric tells the full story. See the ROCO:4162 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PharmaEngine Inc is a biopharmaceutical company engaged in the development of new drugs and therapeutic drugs for cancer. It is a specialty pharma company that adopts the no research, development-only model and the networked pharma model for new drug development. Its key products and pipeline projects include ONIVYDE, a treatment for metastatic pancreatic cancer approved in multiple markets, as well as oncology candidates such as PEP07 and PEP08. It generates revenue from the sales of goods.
78GF Score
Get the complete analysis for ROCO:4162
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4162 has been successfully added to your 
